Astrazeneca (AZN) Revenue (2009 - 2026)
Astrazeneca (AZN) posted quarterly Revenue of $15.4 billion for Q2 2026, up 6.41% year-over-year from $14.5 billion in Q2 2025, and up 19879.22% quarter-over-quarter from $77.0 million in Q1 2026.
Astrazeneca (AZN) Revenue (2009 - 2026) Analysis & Trends
Astrazeneca's Revenue history runs 18 years deep, the most recent figure standing at $15.4 billion for Q2 2026.
- In Q2 2026, Revenue rose 6.41% year-over-year to $15.4 billion; the TTM figure through Jun 2026 stood at $15.5 billion (changed 0.47% YoY), while the FY2025 annual figure was $58.7 billion, up 8.63% from the prior year.
- Revenue for Q2 2026 stood at $15.4 billion, up from $77.0 million in the prior quarter.
- The five-year high for Revenue was $15.4 billion in Q2 2026, with the low at $3.0 million in Q2 2022.
- The 5-year median for Revenue is $87.0 million (2023), against an average of $1.8 billion.
- Peak annual rise in Revenue reached 361325.0% in 2025, while the deepest fall reached 99.26% in 2025.
- Astrazeneca's Revenue stood at $158.0 million in 2022, then surged by 100.63% to $317.0 million in 2023, then soared by 157.1% to $815.0 million in 2024, then slumped by 99.26% to $6.0 million in 2025, then jumped by 256300.0% to $15.4 billion in 2026.
- Business Quant data shows AZN's Revenue at $15.4 billion in Q2 2026, $77.0 million in Q1 2026, and $6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.73 Bn | 631.97 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 469.89 Bn | 463.32 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 377.61 Bn | 370.47 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 257.81 Bn | 252.91 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 237.20 Bn | 223.21 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 159.71 Bn | 148.02 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Gsk | 106.41 Bn | 102.24 Bn | 8.24 Bn | 11.28 Bn |
| 10 | Sanofi | 55.04 Bn | 47.66 Bn | 10.79 Bn | 13.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.38 Bn |
| Mar 31, 2026 | 77.00 Mn |
| Dec 31, 2025 | 6.00 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 14.46 Bn |
| Mar 31, 2025 | 74.00 Mn |
| Dec 31, 2024 | 815.00 Mn |
| Sep 30, 2024 | 59.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 45.00 Mn |
| Dec 31, 2023 | 317.00 Mn |
| Sep 30, 2023 | 97.00 Mn |
| Jun 30, 2023 | 193.00 Mn |
| Mar 31, 2023 | 27.00 Mn |
| Dec 31, 2022 | 158.00 Mn |
| Sep 30, 2022 | 178.00 Mn |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | 258.00 Mn |
| Dec 31, 2021 | 513.00 Mn |
| Sep 30, 2021 | 125.00 Mn |